Global Systematic Lupus Erythematosus Epidemiology and Patient-Based Market Report 2016-2026 - How has the Approval of Benlysta Impacted the Treatment Algorithm and Clinical Trial Design? - Research and Markets

DUBLIN, August 17, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Systematic Lupus Erythematosus: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.

A shift in the systemic lupus erythematosus (SLE) market is forecast over the next 10 years, as new product approvals drive a movement from traditional off-label treatment to prescribing of approved therapies.

This report addresses the following questions:

- How has the approval of Benlysta impacted the treatment algorithm and clinical trial design?

- What will drive growth in the SLE market over the next 10 years, and which patient groups will be most impacted by new product launches?

- What factors have led to the late-phase clinical trial failures that continue to be seen in SLE?

- Which clinical attributes will a new drug need to demonstrate in order to compete in this market?

Key Topics Covered:

FORECAST: SYSTEMIC LUPUS ERYTHEMATOSUS

- Executive Summary

- Market Overview and Trends

- Market Definition and Methodology

- anifrolumab

- Benlysta SLE (belimumab)

- blisibimod

- Primary Research Methodology

EPIDEMIOLOGY: SYSTEMIC LUPUS ERYTHEMATOSUS

- Executive Summary

- Sources and Methodology,

- Forecast,

- Epidemiologist Insight,

- Strengths and Limitations

MARKETED DRUGS: SYSTEMIC LUPUS ERYTHEMATOSUS

- Executive Summary,

- Product Overview,

- Primary Research Methodology,

- Product profile: Benlysta,

- Product profile: Off-label: CellCept,

- Product profile: Off-label: Rituxan

PIPELINE: SYSTEMIC LUPUS ERYTHEMATOSUS

- Executive Summary

- Clinical Pipeline Overview

- Comparator Therapy

- Clinical Trial Design

- The Future of Disease Treatment

- Recently Discontinued Drugs

- Primary Research Methodology

- Product profile (late stage): Lupuzor

- Product profile (late stage): anifrolumab

- Product profile (late stage): atacicept

- Product profile (late stage): blisibimod

For more information about this report visit http://www.researchandmarkets.com/research/xzm9jf/systematic_lupus

Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs

Media Contact:

Laura Wood, Senior Manager

[email protected] 

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com